Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma

作者：Yalei Wen, Hui Wang, Xiao Yang, Yingjie Zhu, Mei Li, Xiuqing Ma, Lei Huang, Rui Wan, Caishi Zhang, Shengrong Li, Hong-Ling Jia, Qin Guo, Xiaoyun Lu, Zhengqiu Li, Xiangchun Shen, Qiushi Zhang, Lu Si, Chengqian Yin, Tongzheng Liu · 发表于：Nature Communications · 年份：2024 · DOI：10.1038/s41467-024-54140-1 · 被引用次数：8 · 研究领域：Protein Degradation and Inhibitors、Ubiquitin and proteasome pathways、Histone Deacetylase Inhibitors Research

Activating mutations in NRAS account for 15–20% of melanoma, yet effective anti-NRAS therapies are still lacking. In this study, we unveil the casein kinase 1δ (CK1δ) as an uncharacterized regulator of oncogenic NRAS mutations, specifically Q61R and Q61K, which are the most prevalent NRAS mutations in melanoma. The genetic ablation or pharmacological inhibition of CK1δ markedly destabilizes NRAS mutants and suppresses their oncogenic functions. Moreover, we identify USP46 as a bona fide deubiquitinase of NRAS mutants. Mechanistically, CK1δ directly phosphorylates USP46 and activates its deubiquitinase activity towards NRAS mutants, thus promoting oncogenic NRAS-driven melanocyte malignant transformation and melanoma progression in vitro and in vivo. Our findings underscore the significance of the CK1δ-USP46 axis in stabilizing oncogenic NRAS mutants and provide preclinical evidence that targeting this axis holds promise as a therapeutic strategy for human melanoma harboring NRAS mutations. Activating NRAS mutations are frequently oncogenic drivers of melanoma; however, attempts to therapeutically target mutant NRAS have remained largely unsuccessful. Here, the authors identify an axis of mutant NRAS regulation wherein casein kinase 1δ (CK1δ) promotes USP46-mediated stabilisation of oncogenic NRAS.